Publications by authors named "Alexander Schuetze"
Article Synopsis
- Breast cancer patients with the CHEK2 c.1100delC variant have a heightened risk of developing a second breast cancer (contralateral breast cancer) and generally experience worse survival outcomes compared to those without the variant.
- A study involving over 82,000 women aimed to evaluate how the CHEK2 variant, radiotherapy, and systemic treatments affect the risk of contralateral breast cancer and breast cancer-specific survival.
- Findings indicated that while systemic therapy (especially the combination of chemotherapy and endocrine therapy) lowers the risk of contralateral breast cancer, CHEK2 c.1100delC carriers still faced poorer survival rates, suggesting other factors at play beyond the risk of developing a second cancer.*
Article Synopsis
- This study is the first phase III trial comparing trabectedin and dacarbazine in patients with advanced liposarcoma or leiomyosarcoma who have previously undergone chemotherapy.
- Patients were randomly assigned to receive either drug, with the primary focus on overall survival and secondary outcomes including progression-free survival and response duration.
- Results showed that trabectedin significantly reduced the risk of disease progression compared to dacarbazine, demonstrating better disease control in this patient population.
